Related Experiment Video

Updated: Dec 10, 2025

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
08:55

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification

Published on: November 20, 2017

10.1K

AntagomiR-29b inhibits vascular and valvular calcification and improves heart function in rats

Ming Fang1,2, Kangyong Liu3, Xinming Li2

  • 1Department of Cardiology, Hainan General Hospital, Haikou, China.

Journal of Cellular and Molecular Medicine
|August 27, 2020
PubMed

Insights

MicroRNA-29b (miR-29b) promotes vascular and valvular calcification by inhibiting TGF-β3. Inhibiting miR-29b reversed calcification, suggesting miR-29b/TGF-β3 targeting for cardiovascular disease treatment.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Calcific aortic valve diseases (CAVD) involve vascular and valvular calcification.
  • The molecular mechanisms underlying CAVD, particularly the role of microRNAs, require further elucidation.

Purpose of the Study:

  • To investigate the role of miR-29b in vascular and valvular calcification.
  • To explore the effect of miR-29b on the transforming growth factor-beta 3 (TGF-β3) pathway in a rat model of CAVD.

Main Methods:

  • A rat model of CAVD was induced using warfarin and vitamin K.
  • Gene and protein expression (miR-29b, osteogenic markers, TGF-β3 pathway components) were analyzed using qRT-PCR, Western blot, immunofluorescence, and immunohistochemistry.
  • Calcium content and alkaline phosphatase (ALP) activity were measured.

Main Results:

  • CAVD model rats exhibited increased calcium content, ALP activity, and osteogenic markers in the aorta and aortic valve.
  • miR-29b expression was upregulated, while TGF-β3 was downregulated in CAVD rats.
  • Administration of antagomiR-29b decreased calcification, normalized miR-29b levels, and restored TGF-β3 expression.

Conclusions:

  • The miR-29b/TGF-β3 axis plays a critical regulatory role in the pathogenesis of vascular and valvular calcification.
  • Inhibition of miR-29b demonstrates therapeutic potential for CAVD and other cardiovascular diseases.

Keywords:
TGF-β3antagomiR-29bmiR-29bvascular calcification

More Related Videos

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.7K
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
743
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
222
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.3K